Laboratorio di Biologia Vascolare e Medicina Rigenerativa, Centro Cardiologico Monzino, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy.
Eur Heart J. 2010 Nov;31(22):2765-73. doi: 10.1093/eurheartj/ehq167. Epub 2010 Jun 9.
Circulating microRNAs (miRNAs) may represent a novel class of biomarkers; therefore, we examined whether acute myocardial infarction (MI) modulates miRNAs plasma levels in humans and mice.
Healthy donors (n = 17) and patients (n = 33) with acute ST-segment elevation MI (STEMI) were evaluated. In one cohort (n = 25), the first plasma sample was obtained 517 ± 309 min after the onset of MI symptoms and after coronary reperfusion with percutaneous coronary intervention (PCI); miR-1, -133a, -133b, and -499-5p were ~15- to 140-fold control, whereas miR-122 and -375 were ~87-90% lower than control; 5 days later, miR-1, -133a, -133b, -499-5p, and -375 were back to baseline, whereas miR-122 remained lower than control through Day 30. In additional patients (n = 8; four treated with thrombolysis and four with PCI), miRNAs and troponin I (TnI) were quantified simultaneously starting 156 ± 72 min after the onset of symptoms and at different times thereafter. Peak miR-1, -133a, and -133b expression and TnI level occurred at a similar time, whereas miR-499-5p exhibited a slower time course. In mice, miRNAs plasma levels and TnI were measured 15 min after coronary ligation and at different times thereafter. The behaviour of miR-1, -133a, -133b, and -499-5p was similar to STEMI patients; further, reciprocal changes in the expression levels of these miRNAs were found in cardiac tissue 3-6 h after coronary ligation. In contrast, miR-122 and -375 exhibited minor changes and no significant modulation. In mice with acute hind-limb ischaemia, there was no increase in the plasma level of the above miRNAs.
Acute MI up-regulated miR-1, -133a, -133b, and -499-5p plasma levels, both in humans and mice, whereas miR-122 and -375 were lower than control only in STEMI patients. These miRNAs represent novel biomarkers of cardiac damage.
循环 microRNAs (miRNAs) 可能代表一类新型的生物标志物;因此,我们研究了急性心肌梗死 (MI) 是否会改变人类和小鼠的血浆 miRNA 水平。
我们评估了 17 名健康供体和 33 名急性 ST 段抬高型 MI (STEMI) 患者。在一个队列 (n = 25) 中,第一份血浆样本是在 MI 症状发作后 517 ± 309 min 获得的,并且在经皮冠状动脉介入治疗 (PCI) 后进行了冠状动脉再灌注;miR-1、-133a、-133b 和 -499-5p 的水平比对照高 15-140 倍,而 miR-122 和 -375 的水平比对照低 87-90%;5 天后,miR-1、-133a、-133b、-499-5p 和 -375 恢复到基线水平,而 miR-122 在 30 天内仍低于对照水平。在另外 8 名患者 (4 名接受溶栓治疗,4 名接受 PCI 治疗) 中,在症状发作后 156 ± 72 min 开始并在随后的不同时间同时定量测定 miRNAs 和肌钙蛋白 I (TnI)。miR-1、-133a 和 -133b 的峰值表达和 TnI 水平出现在相似的时间,而 miR-499-5p 则表现出较慢的时间过程。在小鼠中,在冠状动脉结扎后 15 分钟测量了血浆 miRNA 水平和 TnI,并在随后的不同时间进行了测量。miR-1、-133a、-133b 和 -499-5p 的行为与 STEMI 患者相似;此外,在冠状动脉结扎后 3-6 小时,在心脏组织中发现这些 miRNA 的表达水平呈相反变化。相比之下,miR-122 和 -375 的变化较小,没有明显的调节。在急性后肢缺血的小鼠中,上述 miRNA 的血浆水平没有增加。
急性 MI 上调了人类和小鼠的 miR-1、-133a、-133b 和 -499-5p 血浆水平,而 miR-122 和 -375 仅在 STEMI 患者中低于对照。这些 miRNA 代表心脏损伤的新型生物标志物。